Morphological characteristics of neuroinflammation and gene expression of neurotrophic factors in the brain on the 30th day after traumatic brain injury and administration of the interleukin-1 receptor antagonist
Medical academic journal · 25.12.2025 · 25 (4) · 27-37
DOI: 10.17816/maj643401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical academic journal, online erschienen am 25.12.2025. Verfasst von A. S. Dyatlova und 8 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: A traumatic brain injury causes both primary brain damage and secondary inflammation. This inflammation can contribute to further neuronal damage and dysfunction. Microglial cells are key players in neuroinflammation, which can remain activated for a long time after a traumatic brain injury. Microglial cells are the main source of elevated interleukin-1β (IL-1β) levels in the brain after traumatic brain injury. Therefore, it is essential to investigate their status following the administration of a recombinant IL-1 receptor antagonist (rIL-1Ra), particularly in the long term. The study tested the hypothesis that administration of an IL-1 receptor antagonist during the early post-traumatic period would sufficiently reduce neuroinflammatory activity 30 days after traumatic brain injury. AIM: The study aimed to evaluate the effect of rIL-1Ra on morphological characteristics of microglia in brain areas susceptible to injury, as well as to assess gene expression of neurotrophic factors Bdnf, Ngf, and Vegf and the inflammatory marker S100a12 in the hypothalamus as a potential structure with secondary inflammation on day 30 after traumatic brain injury. METHODS: A drop-weight model was used to induce a diffuse brain injury, and rIL-1Ra was administered subcutaneously at 50 mg/kg one hour after traumatic brain injury, and then twice more over the next two days. Microglial cell activation was assessed using immunohistochemistry and morphometry. The expression of Bdnf, Ngf, Vegf, and S100a12 was determined using a real-time polymerase chain reaction. RESULTS: On day 30 after injury, there were no significant changes in hypothalamic gene expression of neurotrophic factors (Bdnf, Ngf) or S100a12. However, a significant increase in Vegf expression was observed in animals that received rIL-1Ra. Immunohistochemistry showed that activated microglial cells remained in some areas of the brain after treatment, but their numbers were substantially reduced compared to the untreated injured animals. CONCLUSION: rIL-1Ra influences the inflammatory response to traumatic brain injury by reducing microglial activity and enhancing neurotrophic processes. These findings suggest the potential of using rIL-1Ra to treat the sequelae of traumatic brain injury.
Zitieren
APA
Dyatlova, A. S., Novikova, N. S., Filatenkova, T. A., Shanin, S. N., Fomicheva, E. E., Petrunina, E. N., Parshina, Y. S., Ishchenko, A. M., & Serebryanaya, N. B. (2025). Morphological characteristics of neuroinflammation and gene expression of neurotrophic factors in the brain on the 30th day after traumatic brain injury and administration of the interleukin-1 receptor antagonist. Medical academic journal, 25(4), 27-37. https://doi.org/10.17816/maj643401
Vancouver
Dyatlova AS, Novikova NS, Filatenkova TA, Shanin SN, Fomicheva EE, Petrunina EN, et al. Morphological characteristics of neuroinflammation and gene expression of neurotrophic factors in the brain on the 30th day after traumatic brain injury and administration of the interleukin-1 receptor antagonist. Medical academic journal. 2025;25(4):27-37. doi:10.17816/maj643401
BibTeX
@article{Dyatlova2025,
author = {Dyatlova, A. S. and Novikova, N. S. and Filatenkova, T. A. and Shanin, S. N. and Fomicheva, E. E. and Petrunina, Evgeniia N. and Parshina, Y. S. and Ishchenko, A. M. and Serebryanaya, N. B.},
title = {Morphological characteristics of neuroinflammation and gene expression of neurotrophic factors in the brain on the 30th day after traumatic brain injury and administration of the interleukin-1 receptor antagonist},
journal = {Medical academic journal},
year = {2025},
volume = {25},
number = {4},
pages = {27--37},
doi = {10.17816/maj643401}
}
EUVIMED